Effects of Sodium Zirconium Cyclosilicate on Volume Status in Maintenance Hemodialysis: Post Hoc Analysis from the DIALIZE-Outcomes Trial.
Sodium zirconium cyclosilicate did not raise edema rates versus placebo in hemodialysis.
Effects of Sodium Zirconium Cyclosilicate on Volume Status in Maintenance Hemodialysis: Post Hoc Analysis from the DIALIZE-Outcomes Trial.
The Effect of Sodium Zirconium Cyclosilicate on Arrythmia-Related Cardiovascular Outcomes in Participants on Chronic Hemodialysis with Recurrent Hyperkalemia (DIALIZE-Outcomes) trial evaluated the effect of sodium zirconium cyclosilicate (sodium zirconium cyclosilicate) on arrhythmia-related cardiovascular outcomes among patients receiving maintenance hemodialysis.
This post hoc analysis evaluated the effects of sodium zirconium cyclosilicate versus placebo on volume status.
Adults receiving maintenance hemodialysis with predialysis hyperkalemia (serum potassium ≥5.5 mmol/L) were randomized 1:1 to sodium zirconium cyclosilicate (starting dose 5 g once daily on non-dialysis days, titrated as needed; N=1349) or placebo (N=1341).
For the 2690 randomized participants, 62% were male, mean (SD) age was 56.1 (13.4) years, predialysis weight was 75.3 (19.8) kg, and dialysis vintage was 5.9 (5.3) years.
Mean (SD) changes from baseline to end of follow-up were similar between sodium zirconium cyclosilicate and placebo for predialysis systolic (-2.1 [24.3] versus -2.2 [22.2] mm Hg) and diastolic (-0.9 [15.0] versus -0.8 [14.2] mm Hg) blood pressure, and interdialytic weight gain (+0.2 [2.6] versus +0.1 [2.4] kg).
In this post hoc analysis of a large trial of patients with hyperkalemia receiving hemodialysis, there was no clinical evidence of volume changes with sodium zirconium cyclosilicate.
This supports the use of sodium zirconium cyclosilicate as hyperkalemia treatment among patients receiving hemodialysis-a population at high risk for hypervolemia.